Targeted alpha therapy laboratory cyclotron Cyclone® iKure

for astatine-211 production

Overview
Cyclone® iKure is a purpose-built cyclotron engineered for routine, high-volume Astatine-211 (211At) production to support targeted alpha therapies. It provides reproducible, high-yield outputs with workflows and controls adapted to radiopharmacy and clinical supply chains.

Key benefits

• Designed specifically for alpha therapy and industrial-scale At-211 production.
• Automated processes reduce operator interventions and minimize radiation exposure.
• Compact footprint enables installation within standard radiopharmacy infrastructure and lowers site preparation requirements.
• Stable, reproducible production ensuring consistent activity and high radionuclidic purity for clinical use.
• Developed leveraging decades of cyclotron engineering expertise and aligned with applicable regulatory frameworks.

Features

• Purpose-built for routine, high-volume 211At production with process repeatability.
• Compact, safe and operable within constrained facility layouts.
• Automated workflows and target handling to reduce manual steps and operator exposure.
• Manufactured under ISO 9001 processes and designed for CE marking compliance.
• Available production configurations supporting multi-beam operation for increased throughput.

Supporting statements
IBA positions Cyclone® iKure as a solution to accelerate translation of At-211 radiopharmaceuticals from bench to bedside, combining a dedicated production system, ecosystem leadership in At-211 value chain initiatives, and partnerships to scale clinical access to targeted alpha therapies.

Technical specifications

• Energy: 28.5 - 29.5 MeV
• Vault dimensions: 6.5 x 6.5 x 3 m
• Target type: Solid
• Production power: Up to 2 x 200 µAe / 2 x 100 µA particle
• Cyclotron dimensions (footprint): 3 x 3 m